Compelling evidence supports the important role of the receptor in activating the advanced glycation end product axis (ADG) in multiple clinical entities. Since the onset of the 2019 coronavirus pandemic, concerns have been growing about the risk and management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in inflammatory gastrointestinal disorders, such as inflammatory bowel disease (IBD). However, clinical data collected during the pandemic suggest that patients with IBD are not at increased risk of SARS-CoV-2 infection or developing a more severe course of infection.